Eli Lilly oral GLP-1 linked to lower predicted diabetes, CV risk
Lilly said its oral GLP-1, orforglipron, was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease.
Lilly said its oral GLP-1, orforglipron, was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease.